Ongoing Phase 1b/2 Trial of the Allosteric MEK1/2 Inhibitor REC-4881 as Monotherapy (FAP): Updated Safety and Efficacy Najat Khan, Ph.D ., Chief R&D and Chief Commercial Officer and incoming CEO and ...

Najat Khan, PhD, unpacks realistic timelines for AI-based drugs to make clinical impact and her priorities for Recursion as incoming CEO.

Toward the end of this decade, a choice may face the species that could reshape its interactions with intelligence itself and ...

Wang Zhi, dean of the School of Fine Arts, explained, "Through this theme, we aim to anchor intellectual weight in an era of ...

Previously, we watched Tim Berners-Lee knit the world together with the Web, giving us pages to browse and links to click. But a web of information is ...

Two important architectures are Artificial Neural Networks and Long Short-Term Memory networks. LSTM networks are especially useful for financial applications because they are designed to work with ...

Artificial intelligence can already beat grandmasters at Go, draft legal briefs, and generate photorealistic images in ...

Getting good at LeetCode Java can feel like a puzzle sometimes, right? You see all these problems, and you’re not sure where ...

Recursion Pharmaceuticals, Inc. is rated a Sell due to cash burn, Q3 net loss of $162.25M and operational trends. Learn more ...

Recursion Pharma , which uses artificial intelligence to discover new drug candidates, said on Monday its experimental oral drug helped reduce abnormal growths in the colon in patients with a rare ...